Arca
Skip to content
Tools
Tools

Multiple sclerosis

Drug research and approvals for multiple sclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 432 studies of multiple sclerosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 94 drug trials for it since 2013, FDA has 8 approved and 15 open orphan designations naming it, and the EU has 29 authorised medicines for it.

  • Recruiting worldwide: 432
  • Trials authorized in Canada: 94
  • FDA orphan approvals: 8
  • EU medicines: 29

Recruiting now

Newest start dates first, of 432 recruiting on ClinicalTrials.gov ↗

Drug pipeline

31 approved, 52 in phase 3, 66 in phase 2, 46 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Interferon BETA-1A, Teriflunomide, Ocrelizumab, Dalfampridine, Glatiramer acetate, Fingolimod, Ofatumumab, Natalizumab, Dimethyl fumarate, Interferon BETA-1B, Cladribine, Alemtuzumab, Corticotropin, Peginterferon BETA-1A, Ozanimod, Daclizumab, Ponesimod, Prednisone, Diroximel fumarate, Baclofen, Mitoxantrone, Siponimod, Dantrolene, Methylprednisolone hemisuccinate, Dexamethasone, Monomethyl fumarate, Lincomycin, Mycophenolic acid, Triamcinolone acetonide, Prednisolone acetate, Prednisolone phosphoric acid

Rituximab
Phase 3 B-lymphocyte antigen CD20 binding agent
Tolebrutinib
Phase 3 Tyrosine-protein kinase BTK inhibitor
Cyclophosphamide anhydrous
Phase 3 DNA inhibitor
Laquinimod
Phase 3
Nabiximols
Phase 3
Ublituximab
Phase 3 B-lymphocyte antigen CD20 binding agent
Acyclovir
Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
Influenza virus vaccine
Phase 3 Biological vaccine - induces immune response
Acetaminophen
Phase 3 Cyclooxygenase inhibitor
Methylphenidate
Phase 3 Dopamine transporter inhibitor
Memantine
Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
Minocycline
Phase 3 Bacterial 70S ribosome inhibitor
Cholestyramine
Phase 3 Bile acids sequestering agent
Fenebrutinib
Phase 3 Tyrosine-protein kinase BTK inhibitor
Vidofludimus
Phase 3 Dihydroorotate dehydrogenase inhibitor
Biotin
Phase 3
Frexalimab
Phase 3
Methotrexate
Phase 3 Dihydrofolate reductase inhibitor
Onabotulinumtoxina
Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Peginterferon ALFA-2B
Phase 3 Interferon alpha/beta receptor agonist
Terfenadine
Phase 3 Histamine H1 receptor antagonist
Cetirizine
Phase 3 Histamine H1 receptor antagonist
Dexchlorpheniramine
Phase 3 Histamine H1 receptor antagonist
Diphenhydramine
Phase 3 Histamine H1 receptor antagonist
Ergocalciferol
Phase 3 Vitamin D receptor agonist
Amantadine
Phase 3 Glutamate [NMDA] receptor antagonist
Masitinib
Phase 3 Fibroblast growth factor receptor 3 inhibitor
Arbaclofen placarbil
Phase 3 GABA-B receptor agonist
Evobrutinib
Phase 3 Tyrosine-protein kinase BTK inhibitor

Showing the 30 furthest along of 164 in trials.

How its trials ended

3,166 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 666 whose ending is known, 45% met their primary endpoint, 8% missed it and 47% stopped early.

  • Completed, result not reported1,42545%
  • Ongoing67821%
  • Status unknown39713%
  • Met its primary endpoint3009%
  • Stopped: other or unclear1615%
  • Stopped: enrollment or feasibility672%
  • Missed its primary endpoint522%
  • Stopped: sponsor or business decision461%
  • Stopped: lack of efficacy241%
  • Stopped: funding150%
  • Stopped: safety10%

Trials authorized in Canada

The 10 newest of 94; search them all in Canada trials
Sep 17, 2026A phase 3 extension study to investigate long-term safety and tolerability of frexalimab in participants with multiple sclerosisFrexalimab (SAR441344)Sanofi-Aventis Canada IncPending
Apr 29, 2026A phase 3, randomized, double-blind, efficacy and safety study comparing orelabrutinib to placebo in patients with non-active secondary progressive multiple…Orelabrutinib (ICP-022, ZB020)Zenas Biopharma (USA) LLCPending
Apr 28, 2026A phase 3, randomized, double-blind, efficacy and safety study comparing orelabrutinib to placebo in patients with primary progressive multiple sclerosisOrelabrutinib (ICP-022, ZB020)Zenas Biopharma (USA) LLCPending
Apr 9, 2026A phase III, open-label, single-arm, multi-center study to evaluate the safety and use of an on-body delivery system for the subcutaneous home administration…Ocrelizumab (RO4964913)RocheClosed
Dec 22, 2025A phase 1b, open-label, multi-center, randomized study evaluating the safety and tolerability of AZD0120, an autologous CD19/bcma targeting chimeric antigen…AZD0120 (GC012F) / Cyclophosphamide / Fludarabine phosphateAstraZeneca PharmaceuticalsPending
Aug 25, 2025A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive…Remibrutinib (LOU064)Novartis PharmaceuticalsOngoing
Jun 6, 2025A phase 2, randomized, double-blind, four-arm, placebo-controlled, multicenter study assessing the efficacy, safety and tolerability of three doses of orally…BMS-986368Bristol-Myers SquibbOngoing
May 30, 2025The differential effects of thc vs. cbd on cognition in persons with msMPL-013 (tetrahydrocannabinol-cbd) / MPL-014 (cannabidiol-thc)University of CalgaryOngoing
Apr 24, 2025A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab…Remibrutinib (LOU064)Novartis PharmaceuticalsOngoing
Dec 23, 2024Intermittent low oxygen breathing: a first study testing different disease stages in people living with multiple sclerosis (LOXYMS)OxygenUniversity of SaskatchewanOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 23
Sep 18, 2019OzobaxTreatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and…Metacel Pharmaceuticals, LLCApproved
Jan 22, 2010AmpyraTreatment to improve walking in patients with multiple sclerosisAcorda TherapeuticsApproved
Oct 13, 2000NovantroneReducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive…Serono, Inc.Approved
Oct 13, 2000NovantroneReducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive…Serono, Inc.Approved
Dec 20, 1996CopaxoneFor reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.Teva Pharmaceuticals USAApproved
May 17, 1996AvonexTreatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical…Biogen, Inc.Approved
Jul 23, 1993BetaseronIn ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.Chiron Corp. & Berlex LaboratoriesApproved
Jun 25, 1992Lioresal IntrathecalManagement of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable…Medtronic, Inc.Approved
Apr 6, 2020Fixed combination of diroximel fumarate and aspirinTreatment of patients with multiple sclerosis who experience the fumarate flushVitalis, LLCDesignated
Apr 6, 2020Fixed combination of monomethyl fumarate and aspirinTreatment of patients with multiple sclerosis who experience the fumarate flushVitalis, LLCDesignated
Sep 27, 2018Fixed combination of dimethyl fumarate and aspirin (162mg)Treatment of multiple sclerosis in patients who experience dimethyl fumarate flushingVitalis, LLCDesignated
Sep 1, 2015Modified a-cobratoxinTreatment of pediatric multiple sclerosis (0 through 16 years of age).Nutra Pharma CorporationDesignated
Feb 6, 2014T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccineTreatment of Pediatric Multiple SclerosisImmune Response BioPharma, Inc.Designated
Jan 12, 2011Anti-TCR murine monoclonal antibody (MAB, type IgM)Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of ageTolera Therapeutics, Inc.Designated
Apr 30, 2010Glyeraldehyde-3-phosphate dehydrogenaseTreatment of pediatric multiple sclerosisBPT Pharmaceuticals, Inc.Designated

Medicines authorised in the EU

Newest first; 15 of 29
Jun 19, 2026CenrifkiTolebrutinibSanofi Winthrop IndustrieEMA ↗
Jul 28, 2025RiulvyTegomil fumarate · genericNeuraxpharm Pharmaceuticals S.L.EMA ↗
Apr 22, 2024Dimethyl fumarate MylanDimethyl fumarate · genericMylan Pharmaceuticals LimitedEMA ↗
Apr 22, 2024Dimethyl fumarate AccordDimethyl fumarate · genericAccord Healthcare LtdEMA ↗
Apr 22, 2024Dimethyl fumarate NeuraxpharmDimethyl fumarate · genericNeuraxpharm Pharmaceuticals S.L.EMA ↗
Sep 22, 2023TyrukoNatalizumab · biosimilarSandoz GmbHEMA ↗
May 31, 2023BriumviUblituximabNeuraxpharm Pharmaceuticals S.L.EMA ↗
Nov 9, 2022Teriflunomide Viatris (previously Teriflunomide Mylan)Teriflunomide · genericViatris LimitedEMA ↗
Nov 9, 2022Teriflunomide AccordTeriflunomide · genericAccord Healthcare S.L.U.EMA ↗
Nov 15, 2021VumerityDiroximel fumarateBiogen Netherlands B.V.EMA ↗
Aug 18, 2021Fingolimod MylanFingolimod · genericMylan Pharmaceuticals LimitedEMA ↗
May 19, 2021PonvoryPonesimodLaboratoires Juvisé PharmaceuticalsEMA ↗
Mar 26, 2021KesimptaOfatumumabNovartis Europharm LimitedEMA ↗
Sep 24, 2020Fampridine AccordFampridine · genericAccord Healthcare S.L.U.EMA ↗
Jun 25, 2020Fingolimod AccordFingolimod · genericAccord Healthcare S.L.U.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.